Gabrielle Heilek
Research Subjects
Gabrielle Heilek has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amy Ann Lo
Genentech Inc., South San Francisco, California
1 shared publication Anja Blüher
Signature Diagnostics, Potsdam, Germany
1 shared publicationAnn Butcher
Roche Molecular Systems, Inc., 4300 Hacienda Drive, Pleasanton, CA 94588, United States
1 shared publication- Bernd Hinzmann
Roche Sequencing Solutions, Inc., Potsdam, Germany
1 shared publication - Bryan R. Cobb
Roche Molecular Systems Inc., Pleasanton, California, USA
1 shared publication - Charles Havnar
Genentech, South San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
- 1 April 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (4) , 399-406
Innovative Tumor Tissue Dissection Tool for Molecular Oncology Diagnostics
- 1 April 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (4) , 399-406
Open AccessInnovative Tumor Tissue Dissection Tool for Molecular Oncology Diagnostics
- Open Access
- 5 September 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S5) , S8
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment.
- 5 September 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S5) , S8
Open AccessMolecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment.
- 1 August 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 60 (4) , 336-340
HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests
- 1 August 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 60 (4) , 336-340
HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests